You are here:

Archived: levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)

Advice

Following a full submission

levetiracetam (Keppra®) is not recommended for use within NHS Scotland as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.

In the pivotal study, significantly more patients treated with levetiracetam than with placebo had a 50% reduction in the weekly number of myoclonic seizure days in both treatment and evaluation periods.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC. The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
SMC Drug ID: 395/07
Manufacturer: UCB Pharma Ltd
Indication: as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 10 September 2007

Current Advice

Resubmission 11 February 2008

Back